The Numbers That Should Make You Angry
The active ingredient in your $179/month vial of compounded semaglutide costs approximately $59/month in Germany. The branded version — the exact same Ozempic pen, same manufacturer, same molecule — costs roughly $95/month in the UK. The markup is not a rounding error. It is structural, deliberate, and unique to the United States.
The Country-by-Country Breakdown
| Country | Ozempic (semaglutide) | % vs US List | System |
|---|---|---|---|
| 🇺🇸 United States (list) | $969/mo | — | Market-based |
| 🇺🇸 United States (self-pay) | $349/mo | -64% | NovoCare |
| 🇺🇸 United States (compounded) | $99–$199/mo | -79–90% | 503A pharmacy |
| 🇨🇦 Canada | ~$155/mo | -84% | Negotiated |
| 🇬🇧 United Kingdom | ~$95/mo | -90% | NHS/NICE |
| 🇩🇪 Germany | ~$59/mo | -94% | Reference pricing |
| 🇫🇷 France | ~$71–$83/mo | -91–93% | CEPS negotiated |
| 🇦🇺 Australia | ~$87/mo | -91% | PBS subsidized |
The US accounts for approximately 78% of worldwide GLP-1 revenue despite having roughly 4% of the world's population. American patients — whether paying list price, self-pay, or compounded — are subsidizing the rest of the world's access to these medications.
Why the Gap Exists
Reference Pricing Systems
Most developed countries negotiate drug prices at the national level. Germany's reference pricing system, the UK's NICE cost-effectiveness reviews, and Canada's PMPRB (Patented Medicine Prices Review Board) all establish maximum prices that manufacturers must accept to access those markets. The US has historically done none of this for commercial insurance — the IRA's Medicare negotiations are the first meaningful exception.
PBM Markup Structure
The American system includes layers of intermediaries — pharmacy benefit managers, wholesalers, group purchasing organizations — each extracting margin from the drug supply chain. These intermediaries do not exist in most single-payer or reference-pricing systems. The gap between manufacturer cost and patient cost is wider in the US because more entities sit in between.
No Government Price Ceiling
Until the IRA negotiations, pharmaceutical companies could set any US list price they chose. The $969 Ozempic price and $1,349 Wegovy price were not calculated from manufacturing cost; they were set at the maximum the market would bear. In countries with price ceilings, manufacturers accept lower margins rather than lose access to millions of patients.
💡 Importing GLP-1 medications from Canada or Europe is illegal for individual patients under US federal law. The FDA has issued warnings about counterfeit and contaminated products entering through cross-border channels. The international price data here is for context, not a purchasing recommendation.
How International Prices Affect the US Market
The international price gap is not just an academic curiosity — it directly shapes the domestic GLP-1 market in several ways:
Political Pressure
The $59 German price became a talking point in Congressional hearings, the Senate HELP Committee investigation, and White House negotiations. It is difficult for Novo Nordisk to argue that $969 is a fair price when the same company sells the same product for 94% less in Germany. This pressure contributed directly to the NovoCare self-pay program, the LillyDirect vial strategy, and the IRA negotiations.
Compounded Market Justification
The existence of a massive international price gap helps explain why the compounded GLP-1 market grew so rapidly. When the brand-name product costs $969 domestically but $59 internationally, there is enormous economic space for a $149–$299 compounded alternative — even with US-based compounding costs.
Future Price Convergence
The IRA-negotiated Medicare price of ~$274/30-day supply for semaglutide (effective January 2027) represents a step toward international price convergence. At $274, the US price would still be roughly 2–4x the European price, but the gap narrows significantly from the 10–16x multiple at list price.
What This Means for US Patients
You cannot buy European-priced Ozempic. But understanding the international price gap gives you leverage and context:
- The compounded price is not exploitative. At $99–$199/month, compounded semaglutide sits between European government-negotiated prices and US brand self-pay pricing. It is a market-rational price, not a scam.
- Brand-name self-pay programs are still marked up. NovoCare's $349 is still 5–6x the German price. It represents progress, not parity.
- The Medicare Bridge's $50 copay is close to global norms. For eligible beneficiaries, the Bridge program brings the US effectively in line with what Europeans pay. This is unprecedented.
- Prices will continue to converge. As IRA negotiations, TrumpRx initiatives, and generic competition accelerate, the US-to-international gap will narrow — potentially to 2–3x within five years.
The Bottom Line
Americans pay more for GLP-1 medications than any other country by a significant margin. The gap is narrowing faster than anyone predicted in 2023 — thanks to political pressure, direct-to-consumer strategies, and the compounded market providing a price reference point. Until full convergence happens, US patients can access compounded alternatives at prices that are already competitive with some international markets.
⚠️ Compounded GLP-1 medications are not FDA-approved. Importing prescription medications from outside the US is illegal under federal law. This article is for informational and comparative purposes only. Always consult a licensed US clinician and use licensed US pharmacies.